Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 28

Results For "US"

9279 News Found

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Drug Approval | November 14, 2025

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor


Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
Technology | November 14, 2025

Terumo BCT and Santersus partner to advance blood purification therapy for sepsis

Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses


Hormone therapy for menopause gets green light from FDA
News | November 14, 2025

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature


Novartis opens radioligand therapy facility in Carlsbad, US
News | November 14, 2025

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio


NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million
News | November 13, 2025

NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million

Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex


FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma
Drug Approval | November 12, 2025

FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma

Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition


Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
Clinical Trials | November 11, 2025

Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia

The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life


Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
News | November 10, 2025

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives


Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
News | November 10, 2025

Venus Remedies expands ASEAN presence with new drug approvals in Vietnam

Venus Remedies now has 29 active product approvals in Vietnam alone